ALFA Finder| Margins | EBITDA margin 30.4% vs 30.9% Q1FY27, 46.4% Q2FY26 |
|---|---|
| Demand visibility | Intl formulations ₹6,684Mn vs ₹11,402Mn; domestic ₹1,457Mn vs ₹1,054Mn |
Growth
Revenue down 30.3% YoY, up 28% QoQ; PAT down 61% YoY to ₹2,026Mn (incl. ₹292Mn associate share).
Outlook
No explicit guidance given; expanding US pipeline (29 Para IVs), NRC-2694 Phase 2 trial, kidney xenotransplant trial registration early 2027.
Risks
Sharp YoY fall in international formulations (₹11,402Mn to ₹6,684Mn); margin compression vs Q2FY26 (46.4%).
Investor Presentation filed with NSE, NSE: NATCOPHARM. Summary written with AI assistance from the document.
Natco Pharma Ltd: key numbers
- Share price
- ₹802.00
- Market cap
- ₹15,733 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 13.8×Sector 43.8×
- Promoter holding
- 46.22%-3.20% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natco Pharma Ltd
All →Natco Pharma Dividend
Natco Pharma declared 2nd interim dividend of Rs.1.25 per share for FY26-27. Record date is November 19, 2026; payment begins November 27.
Natco Pharma Q2 FY27 Results: Net Profit ₹202.6 Cr, Down 60.9% YoY
Natco Pharma Ltd reported revenue from operations of ₹967.3 Cr (-29.0% YoY) and net profit of ₹202.6 Cr (-60.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹202.6 Cr · -60.9% YoY
Natco Pharma Share Pledge
Natco Pharma promoter V.C. Nannapaneni pledged 8,50,000 equity shares to Bajaj Financial Securities Limited. The pledge supports the promoter's subscription to the company's Rights Issue.
Natco Pharma Other Announcement
Natco Pharma filed its shareholding pattern with a reporting date of 23 October 2026. Promoter and promoter group hold about 46% of total equity.
Natco Pharma Capital Structure Change
Natco Pharma allotted 5,86,666 equity shares to promoter Venkaiah Chowdary Nannapaneni via its rights issue, valued at ~₹44 Crore. This lifts his stake to 14.60%.
- Value
- ₹44.00 Cr
Natco Pharma Employee Stock Options
Natco Pharma's insiders, including promoters and directors, were allotted equity shares. This allotment increases their total shareholding in the company.
- Value
- ₹144.2 Cr